All you need to know in one place
Privo Technologies to Receive $900,000 of Investment Funding Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for…
On Childhood Cancer Day, SHEPHERD Therapeutics is joining forces with Oncoheroes Biosciences to bring new treatment options to children and adolescents with cancer. SHEPHERD is a Boston-based biotech company on a mission to change the way rare cancer is treated,…
Every year, people around the world connect on a special day to support and remember the families and individuals affected by cancer. This day is called World Cancer Day, on February 4th. Over the past two decades, World Cancer Day…
An additional venture philanthropy organization, the Catalytic Impact Foundation, which supports women’s health, brain health, children’s health, aging, and pediatric rare disease initiatives, is investing in AIM-HI Accelerator Fund portfolio company Oncoheroes Biosciences, further validating the start-up’s unique effort to…
The AIM-HI Accelerator Fund is proud to support our Portfolio Company, SciTech Development, to present at the Virtual 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event will take place on January 11-12, 2021, co-hosted…
The AIM-HI Accelerator Fund sincerely thanks Microsoft for being a generous sponsor and supporting our inaugural Women’s Venture Competition program to provide various opportunities to women-led oncology start-ups! Only 2% of all venture money go to women-led early stage companies.…
Tvardi Therapeutics, an AIM-HI Accelerator Fund portfolio company, has won recognition as one of the ten “Most Promising” companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is…
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare…
Congratulations to the inaugural AIM-HI Women’s Venture Competition finalists selected by the Judging Committee, Stacy Blain of Concarlo Holdings and Manijeh Goldberg of Privo Technologies. Not only are they advancing science, but they are also paving the way for more…
It’s 2020, and still only 2.2% of all venture capital dollars go to companies led by women entrepreneurs in life sciences. Let’s change that! Join us on Thursday, September 24, at the AIM-HI Women’s Venture Competition Award Ceremony as we celebrate…
